Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Net Cash Flow (2020 - 2025)

RxSight (RXST) has disclosed Net Cash Flow for 6 consecutive years, with -$9.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow fell 26952.78% year-over-year to -$9.7 million, compared with a TTM value of $3.2 million through Dec 2025, down 54.11%, and an annual FY2025 reading of $3.2 million, down 54.11% over the prior year.
  • Net Cash Flow was -$9.7 million for Q4 2025 at RxSight, up from -$10.7 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $29.6 million in Q2 2022 and bottomed at -$43.7 million in Q4 2021.
  • Average Net Cash Flow over 5 years is $313200.0, with a median of -$68500.0 recorded in 2023.
  • The sharpest move saw Net Cash Flow skyrocketed 5507.54% in 2021, then crashed 26952.78% in 2025.
  • Year by year, Net Cash Flow stood at -$43.7 million in 2021, then skyrocketed by 106.55% to $2.9 million in 2022, then tumbled by 106.05% to -$173000.0 in 2023, then skyrocketed by 120.81% to $36000.0 in 2024, then plummeted by 26952.78% to -$9.7 million in 2025.
  • Business Quant data shows Net Cash Flow for RXST at -$9.7 million in Q4 2025, -$10.7 million in Q3 2025, and $12.3 million in Q2 2025.